Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.76)
# 698
Out of 5,149 analysts
14
Total ratings
83.33%
Success rate
28.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARMP Armata Pharmaceuticals | Initiates: Buy | $15 | $11.36 | +32.04% | 1 | Jan 5, 2026 | |
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $40.07 | +59.72% | 2 | Dec 1, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Hold | n/a | $13.61 | - | 2 | Nov 11, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $34.09 | +34.94% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $13.96 | +71.92% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $5.62 | +380.43% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $3.94 | +889.85% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $15.61 | +92.18% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $14.10 | +63.12% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $26.78 | +71.80% | 1 | Sep 19, 2024 |
Armata Pharmaceuticals
Jan 5, 2026
Initiates: Buy
Price Target: $15
Current: $11.36
Upside: +32.04%
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $40.07
Upside: +59.72%
Intellia Therapeutics
Nov 11, 2025
Downgrades: Hold
Price Target: n/a
Current: $13.61
Upside: -
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $34.09
Upside: +34.94%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $13.96
Upside: +71.92%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $5.62
Upside: +380.43%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $3.94
Upside: +889.85%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $15.61
Upside: +92.18%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $14.10
Upside: +63.12%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $26.78
Upside: +71.80%